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Abstract. Hepatitis Β virus (HBV) infection is considered as 
one of the major risk factors in the development of human 
hepatocellular carcinoma (HCC). Recent studies have also 
suggested the implication of oncogene and onco-suppressor 
genes in liver carcinogenesis. We studied 41 cases of HCC 
for the presence of HBV DNA and point mutations in codon 
12 of K-ras and codon 249 of p53. We used 'nested' PCR for 
the amplification of HBV because of the expected low 
incidence of the virus DNA in the samples. PCR was also 
used for the amplification of K-ras and p53 regions that 
contain the codons of interest, followed by RFLP analysis for 
the detection of point mutations. HBV DNA was amplified in 
22 cases (53.7%), while 5 cases (12.2%) appeared to carry 
mutations in codon 12 of K-ras and 7 cases (17.1%) had 
mutations in codon 249 of the p53 gene. These results further 
support the correlation between HBV infection and HCC and 
also indicate an implication of K-ras and p53 genes in 
hepatocarcinogenesis. 
Introduction 
Hepatocellular carcinoma is the most frequent primary liver 
tumor with 5xl05 to 106 new cases a year and hepatitis Β 
virus infection is thought to be one of the major risk factors 
(1). HBV oncogenic activity is possibly based on the 
integration of the viral DNA into the cellular genome, 
disrupting the normal regulation of certain genes, but the 
precise molecular mechanism remains to be elucidated (2). 
K-ras gene is a member of the ras family encoding for a 
21 Kd protein which appears to play a key role in the signal 
transduction pathway and is also found activated in human 
cancers. K-ras gene mutations have been found to be 
infrequent in HCC (3-5). 
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p53 gene is thought to act as a tumor-suppressor gene, 
regulating the entry of the cell into the S phase of the cell 
cycle. Mutations in p53 are frequent in many types of human 
neoplasms. One of the identified 'hot spots' in p53 is codon 
249 presenting G->T transversions in HCC cases, thus giving 
a possible correlation between p53 mutations and aflatoxin 
Bl which is known to cause such transversions in G-C rich 
DNA regions and is considered as another risk factor for 
development of HCC in Asian and African countries (6). 
The polymerase chain reaction (PCR) is a powerful 
method for the detection of specific DNA sequences with 
many clinical applications due to its great sensitivity and 
specificity and it has been employed successfully before for 
the detection of HBV (7,8). For the detection of mutations in 
K-ras and p53 we employed the restriction fragment length 
polymorfism (RFLP) analysis since it is a rapid, non­
radioactive method and it has been used successfully in the 
past (9,10). Briefly, the detection of a point mutation by 
RFLP is based on the digestion of the PCR product with a 
chosen restriction enzyme that recognizes a sequence 
containing the exanined codon. A point mutation in this 
codon will lead to loss of the restriction site and after the 
digestion the PCR product will be intact. 
Our study on the frequency of HBV DNA and mutations 
in K-ras and p53 genes in HCC cases in Greece shows that 
53.7% carried HBV, 12.2% K-ras mutations at codon 12 and 
17.1% p53 mutations at codon 249. 
Materials and methods 
DNA extraction. Three 10 μ thick sections from paraffin 
embedded tissues were put in 1.5 ml eppendorf tubes and 300 
μΐ lysis solution containing 0.1 Ν NaOH/ 2M NaCl was 
added. Samples were then boiled for 5 min and 
microcentrifuged for another 5 min at 4°C. Supernatants were 
transferred into fresh tubes and DNA was precipitated with 
the addition of 1 ml of ethanol. DNA was recovered by 
centrifugation for 15 min at 4°C, washed twice with cold 
70% ethanol and resuspended in 20 μΐ distilled water. 
Oligonucleotide primers and PCR amplification. Two sets of 
oligonucleotides were used for the amplification of HBV: 
Primer 1763 (5' GCT TTG GGG CAT GGA CAT TGA CCC 
GAA TAA 3') and primer 2032 (5' CTG ACT ACT AAT 
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Table I. Hepatitis Β virus DNA and mutations in K-ras and p53 genes in hepatocellular carcinomas. 
No Age Grade Cirrhosis HBV K-ras 2 codon 12 mutation p53 codon 249 mutation 
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ND: no data available. 
TCC CTG GAT GCT GGG TCT 3') were used for the first 
amplification and primer 1778 (5' GAC GAA TTC CAT 
TGA CCC GTA TAA AGA ATT 3') and primer 2017 (5' 
ATG GGA TCC CTG GAT GCT GGG TCT TCC AAA 3') 
were used for the nested PCR. The oligonucleotides for K-
ras codon 12 amplification were K5 (5' ACT GAA TAT 
AAA CTT GTG GTA GTT GGA CCT 3') and K3 (5' TCA 
AAG AAT GGT CCT GGA CC 3'). The oligonucleotides for 
p53 codon 249 were 18004 (5' CTG GAG TCT TCC AGT 
GTG AT 3') and 18005 (5' GTT GGC TCT GAC TGT ACC 
AC 3'). 1 μΐ of the extracted DNA of each sample was 
amplified in a volume of 50 μΐ containing 16.6 mM 
(NH4),S04, 10 mM, ß-mercaptoethanol, 6.7 mM MgCl2, 67 
mM Tris-HCl pH 8.8, 1.7 mg BSA, 200 μΜ of each dNTP, 
250 ng of each primer and 2.5 U Taq polymerase (Perkin 
Elmer Cetus). Amplification was performed in a thermal 
cycler (Perkin Elmer Cetus) using the following parameters: 
(i) HBV amplification: 94°C for 35 sec, 42°C for 40 sec, 
72°C for 50 sec, 35 cycles (for both first and nested PCR). 
Reactions for HBV contained 10% DMSO. (ii) K-ras 
amplification: 94°C for 40 sec, 60°C for 45 sec, 72°C for 50 
sec, 40 cycles, (iii) p53 amplification: 95°C for 30 sec, 58°C 
for 30 sec, 72°C for 50 sec, 35 cycles. 
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RFLP analysis, (i) K-ras: 10-20 μΐ aliquots of the 
amplification products were digested for 3 h with 20 U 
BstNI. (ii) p53: 10-20 μΐ aliquots of the amplification 
products were digested overnight with 20 U Hae III. Enzymes 
were supplied by New England Biolabs and the conditions 
followed for digestions were those recommended by the 
supplier. Incubation temperatures were 60°C for BstNI and 
37°C for Haelll. Digestion products were electrophoresed 
through an 8% native polyacryamide or a 2% agarose gel. 
Gels were stained with ethidium bromide and photographed 
on a UV light transilluminator. 
Statistical analysis. Statistical analysis was performed on a 
Macintosh computer with the help of STATWORK (version 
1.2) software. 
Results 
Forty one cases of HCC, with known serological markers for 
HBV infection and cirrhosis in some cases, were studied as 
shown in Table I. 
In order to increase the sensitivity of the method for the 
detection of HBV which characteristically has a low copy 
number per cell we used 'nested' PCR, performing 
reamplification of the PCR products with the use of a pair of 
primers internal to those used in the first PCR. No positive 
samples were found after the first PCR while 22 positive 
samples (53.7%) for HBV DNA were found after the nested 
PCR. These are represented with a 258 bp DNA band on the 
gel and they were classified as intensely (+++), moderately 
(++) or weakly (+) positive according to the intensity of the 
band (Fig. 1). 
Five cases carrying mutations in codon 12 of K-ras were 
also detected as judged from the presence of a 143 bp DNA 
band on the gel (Fig. 2) and 7 cases carrying mutations in 
codon 249 of p53 gene as determined from the presence of a 
110 bp DNA band on the gel (Fig. 3). Among the examined 
samples there was an interesting case found positive for HBV 
and carrying mutations in the both K-ra.v and the p53 genes. 
The results are summarized in Table I. 
Discussion 
The results described in this study indicate that HBV infection 
is one of the major risk factors for the development of HCC. 
The statistical analysis showed that the presence of HBV 
DNA is not correlated (P<0.05) with the tumor grade 
suggesting that HBV infection can occur as an early event in 
hepatocarcinogenesis. The presence of point mutations in K-
ras and p53 genes further support a possible role of these 
genes in the development of the disease and provide evidence 
that liver carcinogenesis is a multistage process. 
Some interesting conclusions can be drawn from a 
comparison of our results to those of previous studies from 
our group (11,12) in which we studied HBV/tumor markers 
and the expression of ras, myc and erbB-2 oncogenes in 21 
out of the 41 tumors presented in this study, using 
immunohistochemical techniques. The first obvious 
conclusion is that PCR is much more sensitive in the detection 
of the virus than immunohistochemical methods. Also, the 
statistical analysis showed no correlation (P<0.05) between 
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Figure l. Detection of HBV DNA in hepatocellular carcinomas by nested 
PCR. Amplification products were electrophoresed through a 2% agarose 
gel. Lane l: pUCI8/HaeIII molecular marker, lane 2: negative control, lanes 
8, 9, 12: negative samples, lanes 3, 4, 6, 10: weakly positive samples, lanes 
5, 7, 11, 14: moderately positive samples, lanes 13, 15: intensely positive 
samples. 
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Figure 2. Detection of K-ra.v codon 12 mutations by PCR-RFLP. PCR 
products after digestion with BstNI were electrophoresed through an %c/c 
acrylamide gel. Lane 1: positive control (SW480 cell line), lanes 5, 9: 
positive samples, lane 15: pUC18/HaeIII molecular marker. 
Figure 3. Detection of p53 codon 249 mutations by PCR-RFLP. PCR 
products after digestion with Haelll were electrophoresed through a 2% 
agarose gel. Lanes 1, 9: positive controls, lanes 2, 3, 4, 5: positive samples, 
lanes 6, 7, 8: negative samples, lane 10: pUC18/HaeIII molecular marker. 
the presence of HBV DNA and the expression of ras and myc 
genes indicating no disturbance of the regulation of these 
genes by the viral genome in the examined tumors. 
Concerning the point mutations in codon 12 K-ras gene, 
we found higher frequency compared to other studies where 
only 2 out of 43 (5) or no mutations in this codon have been 
found (4,6). 
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Furthermore, it is of interest that we have found a 17.1% 
frequency of p53 codon 249 mutations in HCC in Greece as 
compared to high mutation frequencies (3,13,14) and low 
mutation frequencies (15,16) in some African and Asian 
countries. It has been suggested that aflatoxins could account 
for this increased p53 mutation frequency (13,14). 
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